drugset / Trial / NCT07261592
Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer
Phase 1/2
Not yet recruiting
29 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NaSingle-groupOpen-labelTreatment
Summary
This single-center single-arm, open-label prospective clinical trial aimed to evaluate the efficacy and safety of entinostat combined with chemotherapy as second-line therapy for unresectable locally advanced or metastatic bladder cancer.
Timeline
- Start
- 2025-12-01
- Primary completion
- 2028-09-30
- Completion
- 2029-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entinostat | Small molecule | 5 mg | Oral |
| Background | Cisplatin | Other / unclassified | 70 mg/m2 | Intravenous |
| Background | Gisantinib | Unknown | 1000 mg/m2 | Intravenous |